The etiology of osteochondritis dissecans is described as idiopathic. No inheritance patterns or causative genes are certified in this packet.

Diagnosis relies on imaging to identify subchondral bone lesions, assess fragment stability, and determine joint involvement—particularly in the knee, ankle, or elbow. No additional certified diagnostic criteria are documented in this packet.

No certified approved pharmacological treatments are documented in this packet. Allogeneic human chondrocytes (Vanarix SA) holds an orphan designation specifically for treatment of osteochondritis dissecans. A separate orphan-designated product, recombinant human platelet-derived growth factor-BB (Biomimetic Therapeutics), was withdrawn and is not a current treatment option.

Prognosis is not certified in this packet. Sequestrum detachment and secondary osteoarthritis are documented as potential sequelae in the disease definition.

A Phase 3 study (NCT03588975, Vericel Corporation) is evaluating MACI in patients aged 10–17 with symptomatic chondral or osteochondral defects of the knee. A long-term prospective cohort (NCT02771496, University of Pennsylvania) is ongoing. Boston Children's Hospital is studying psychological response associated with knee OCD (NCT04649905). The published literature includes 142 classified articles, with reviews and meta-analyses as the dominant type.